Immunotherapy: MAPK‐Targeted Drug Delivered by a pH‐Sensitive MSNP Nanocarrier Synergizes with PD‐1 Blockade in Melanoma without T‐Cell Suppression (Adv. Funct. Mater. 12/2019)
Abstract
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Immune cells in cancer · Cancer Immunotherapy and Biomarkers
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Laboratory of Tumor Targeted and Immune Therapy Clinical Research Center for Breast State Key Laboratory of Biotherapy West China Hospital Sichuan University and Collaborative Innovation Center Chengdu Sichuan 610041 China
Laboratory of Chemical Biology Changchun Institute of Applied Chemistry Chinese Academy of Sciences Changchun Jilin 130022 China
University of Science and Technology of China Hefei Anhui 230026 China
Laboratory of Anesthesiology and Critical Care Medicine Translational Neuroscience Center, West China Hospital Sichuan University Chengdu Sichuan 610041 China
Conmed Biosciences Inc. Chengdu Sichuan 61004 China
College of Pharmacy and Biological Engineering Chengdu University Chengdu Sichuan 610106 China
MOH Key Laboratory of Gastroenterology and Hepatology State Key Laboratory for Oncogenes and Related Genes Renji Hospital School of Medicine Shanghai Jiao Tong University Shanghai 200240 China
Division of NanoMedicine Department of Medicine University of California Los Angeles CA 90095 USA
References
Reference metadata was not supplied for this record.